Omada Health
NASDAQ:OMDAMedical - Healthcare Information Services
+$0.13 today
- Market cap
- $817.04M
- Beta
- 2.09
- P/E (TTM)
- -162.6
- EPS (TTM)
- -$0.11
Volume 1.68M
Average 1.07M
OMDA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Omada HealthNASDAQ: OMDA
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow dips below year-ago levels
Q1 FY2026 free cash flow of $11.91M (cash outflow) fell 31.4% year over year, behind the +163.1% change in trailing-twelve-month free cash flow.
Context
- Free cash flow amounted to 6.5% of revenue in FY2025, down 15.9 pp from a year earlier.
- Free cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -31.4% toward the trailing-twelve-month pace of +163.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 16.93M USD
- Year-over-year change
- +144.5%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.93M | +144.5% |
| FY2024 | 2024-12-31 | (38.04M) | +27.8% |
| FY2023 | 2023-12-31 | (52.66M) | +26.6% |
| FY2022 | 2022-12-31 | (71.7M) | — |
Free Cash Flow vs competitors
How OMDA compares with its peers on the latest reported figures
- OMDA's LTM Mar 2026 free cash flow of $21.45M is the smallest of the 5 companies compared; the peer median is $140.84M.
- Its year-over-year change of +163.1% is the 2nd highest of 5, against a peer median of -19.3%.
- Free cash flow amounts to 7.6% of revenue for OMDA, versus a peer median of 13.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $287.33M | +226.7% | — | 39.9% | |
| LTM Mar 2026 | $251.09M | +21.7% | +18.2% | 10.0% | |
| LTM Mar 2026 | $41.85M | -60.2% | -31.2% | 17.6% | |
| LTM Sep 2026 | $30.58M | -76.8% | — | 1.1% | |
| LTM Mar 2026 | $21.45M | +163.1% | — | 7.6% | |
| Peer median (excluding OMDA) | $140.84M | -19.3% | -6.5% | 13.8% | |
Competitors are the stored peer set for OMDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (72.52M) | (67.51M) | (47.14M) | (12.78M) |
| Depreciation & Amortization | 4.33M | 4.45M | 4.8M | 5.49M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.65M | 8.74M | 9.42M | 12.96M |
| Change in Working Capital | (9.15M) | (1.5M) | (6.57M) | 3.74M |
| Accounts Receivables | (3.93M) | (5.34M) | (8.81M) | (12.36M) |
| Inventory | (1.95M) | (74K) | 318K | (1.19M) |
| Accounts Payables | (4.99M) | (286K) | 399K | 6.29M |
| Other Working Capital | 1.73M | 4.2M | 1.52M | 11M |
| Other Non-Cash Items | 1.7M | 6.09M | 5.3M | 8.85M |
| Operating Cash Flow | (68.98M) | (49.74M) | (34.18M) | 18.25M |
| Capital Expenditures | (2.72M) | (2.92M) | (3.86M) | (1.32M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | (2M) | (2.51M) | (3.27M) | (4.51M) |
| Investing Cash Flow | (2.72M) | (2.92M) | (3.86M) | (5.83M) |
| Debt Repayment | (1.27M) | 963K | 0 | (30.96M) |
| Common Stock Issued | 1.74M | 1.76M | 3.33M | 169.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.27M | (2.54M) | (4.54M) | (5.71M) |
| Financing Cash Flow | 16.32M | 179K | (1.21M) | 133.22M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (55.38M) | (52.48M) | (39.25M) | 145.64M |
| Free Cash Flow | (71.7M) | (52.66M) | (38.04M) | 16.93M |
Omada Health
NASDAQ:OMDA
Intrinsic Alpha fair value
Locked
Current Price
$13.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.